Xtandi®, Enzalutamide, is indicated for:
- the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC)
- the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
- the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy
